OF 18-METHOXYCORONARIDINE , AN IBOGAINE ANALOG , TO 18-HYDROXYCORONARIDINE BY GENETICALLY VARIABLE CYP 2 C 19
Wenjian Zhang,Yamini Ramamoorthy,R. Tyndale,S. D. Glick,I. M. Maisonneuve,M. Kuehne,E. Sellers
Abstract:18-Methoxycoronaridine, a newly developed ibogaine analog, has been reported to decrease the self-administration of morphine, cocaine, ethanol, and nicotine. It has also been reported to attenuate naltrexone-precipitated signs of morphine withdrawal. In this study, three metabolites of 18-methoxycoronaridine (18-MC) were separated and identified by high-performance liquid chromatography-electrospray ionization-mass spectrometry-mass spectrometry (HPLC-ESI-MS-MS); the major metabolite was 18-hydroxycoronaridine (18-HC). The other two metabolites were elucidated as hydroxylated metabolites on the basis of their MS-MS spectra. Catalytic studies of 18-MC O-demethylase activity in human liver microsomes indicate that one high affinity enzyme is involved in this reaction (Km from 2.81 to 7.9 M; Vmax from 0.045 to 0.29 nmol/mg/min). In cDNA-expressing microsomes, only CYP2C19 displayed significant 18-MC O-demethylase activity (Km 1.34 M; Vmax 0.21 nmol/mg/min). S-Mephenytoin, a selective CYP2C19 inhibitor, inhibited 18-MC O-demethylation by 65% at a concentration of 2 times its KI, and antibodies against rat 2C (human CYP2C8, 2C9, 2C19) inhibited 18-HC formation by 70%. Studies with other cytochrome P450 (P450)-selective chemical inhibitors and antibodies failed to demonstrate an appreciable role for other P450s in this reaction. In addition, in microsomes from five different human livers, 18-MC O-demethylation correlated with S-mephenytoin 4 hydroxylase activity but not with other P450 probe reactions. These data indicate that 18-HC formation is the predominant pathway of 18-MC metabolism in vitro in human liver microsomes and that this metabolic pathway is primarily catalyzed by the polymorphic CYP2C19. The apparent selectivity of this pathway for CYP2C19 suggests 18-MC as a potentially useful probe of CYP2C19 activity in vitro and in vivo. Ibogaine, an iboga alkaloid extracted from the root bark of the African shrub Tabernanthe iboga, has been observed to be effective in the treatment of opiate addiction and stimulant abuse (Alper et al., 1999; Mash et al., 2000). 18-Methoxycoronaridine (18-MC) (Fig. 1), a newly developed ibogaine analog, has been reported to decrease the self-administration of morphine, cocaine, ethanol, and nicotine, and to attenuate naltrexone-induced morphine withdrawal in rat models (Glick et al., 1996, 1998, 1999; Maisonneuve and Glick, 1999). In addition to having stimulant and hallucinogenic properties, ibogaine induces tremors and, at high doses, damages the cerebellum (Dzoljic et al., 1988; Glick et al., 1991, 1992, 1994; Cappendijk and Dzoljic, 1993; O’Hearn and Molliver, 1993; Sershen et al., 1994). 18-MC, therefore, requires further study as a potentially useful therapeutic agent in the treatment of opiate and psychostimulant addiction, as well as for opiate withdrawal. Prior to beginning clinical trials, it is necessary to identify the metabolites of 18-MC, as well as the enzymes involved in its metabolism. Cytochrome P450s (P450s) play a major role in the metabolism of endogenous and exogenous compounds. Over 20 P450 isoforms have now been characterized, eight of which have been shown to be the major enzymes involved in the oxidative metabolism of drugs (CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4) (Shimada et al., 1994). The polymorphic human isoform CYP2C19 contributes to the metabolism of many therapeutically important drugs (Michalets, 1998). The poor metabolizer (PM) phenotype, constituting those homozygous for inactive alleles and therefore having no CYP2C19 activity, occurs with a frequency of 2.5 to 6% in Caucasians. Higher frequencies are observed in Chinese (15–17%) and Japanese (18– 23%) populations (Inaba et al., 1984; Wedlund et al., 1984; Jurima et al., 1985; Nakamura et al., 1985; Horai et al., 1989; Bertilsson et al., 1992). PMs may be more likely to experience adverse drug effects due to increased plasma concentration and/or increased half-life of the parent drug. For drugs that require CYP2C19-catalyzed bioactivation Supported in part by National Cancer Institute Grant CA-12010 and National Institute on Drug Abuse Grants DA-03817 and DA-06889. 1 Abbreviations used are: 18-MC, 18-methoxycoronaridine; P450, cytochrome P450; PM, poor metabolizer; HPLC, high-performance liquid chromatography; 18-HC, 18-hydroxycoronaridine; ESI, electrospray ionization; MS, mass spectrometry; -NP, -naphthoflavone; PL, pilocarpine; OP, orphenadrine; SP, sulfaphenazole; S-MP, S-mephenytoin; BD, budipine; DDC, diethyldithiocarbamate;